DOTATATE PET Scan

What It Shows

• Primary neuroendocrine tumour location and extent
• All NET metastases simultaneously — liver, lymph nodes, bone, peritoneum, lungs
• Somatostatin receptor expression level — predicts response to SSA therapy and PRRT
• Unknown primary NET — DOTATATE often localises the primary when CT cannot
• Disease extent before PRRT (177Lu-DOTATATE / Lutathera) — required for eligibility assessment
• Response to PRRT — post-therapy DOTATATE imaging confirms treatment effect
• Paraganglioma and phaeochromocytoma (SSTR2-expressing variants)
• Medullary thyroid cancer, Merkel cell carcinoma in selected cases

How It Works

68Ga-DOTATATE is injected intravenously. The DOTATATE peptide binds to somatostatin receptors (primarily SSTR2) expressed on NET cells. PET imaging 45–90 minutes post-injection detects gamma rays from gallium-68 decay. CT acquired simultaneously provides anatomical correlation. The scan covers the whole body. Physiological DOTATATE uptake occurs in the spleen, pituitary, adrenal glands, uncinate process of pancreas, and kidneys — the reporting physician accounts for these normal areas of uptake.

• Diagnosis and staging of known or suspected NETs
• Localising unknown primary NET
• Before starting somatostatin analogue therapy (lanreotide/octreotide) — to confirm receptor expression
• PRRT eligibility assessment (177Lu-DOTATATE / Lutathera) — SSTR2 expression required
• Monitoring NET disease progression or response
• Distinguishing NET from non-NET lesions in patients with multifocal disease

DOTATATE PET has replaced octreotide scintigraphy (OctreoScan) as the gold standard for NET imaging. The NETSPOT registration trial (N=78) showed sensitivity 96%, specificity 100% per lesion. Multiple comparative studies demonstrate DOTATATE PET detects 2–4 times more lesions than CT or OctreoScan alone. The NETTER-1 trial (NEJM 2017) — which established 177Lu-DOTATATE (Lutathera) as a therapeutic option — required positive DOTATATE scan for enrolment, establishing it as the predictive biomarker. DOTATATE PET is FDA-approved (Netspot, Illuccix) and recommended by NCCN, ESMO, and ENETS guidelines.

Preparation & What to Expect

Somatostatin analogue therapy (octreotide/lanreotide) should be withheld for at least 4 weeks (long-acting) or 24 hours (short-acting) before scan — SSAs compete for somatostatin receptors and reduce tracer uptake. No fasting required. No glucose restrictions. Arrive 30 minutes early. Total appointment 2–3 hours.

• Only works for SSTR2-expressing tumours — high-grade NETs (Grade 3, Ki-67 > 20%) often lose receptor expression and are FDG-avid instead
• Physiological uptake in spleen, pituitary, adrenals, and pancreatic uncinate process can complicate interpretation
• Small bowel NETs can be difficult to separate from adjacent normal bowel uptake
• Requires specialist nuclear medicine reporting with NET expertise

• SSA therapy MUST be withheld before scan — speak to your NET team about timing
• Radiation exposure is low but present — avoid in pregnancy
• Do not confuse DOTATATE scan result with PRRT eligibility — formal eligibility assessment by NET team required even with positive scan